Jan 10, 2013 by Dave Williamson and austin smithDendreon: The Opportunity for InvestorsDavid Williamson talks about the buzz behind Dendreon.
Jan 7, 2013 by Dave WilliamsonThe Companies in the 2013 Hot SeatLearn About The Companies in The 2013 Hotseat
Jan 6, 2013 by Dave Williamson and Chris HillThe Most Exciting Biotech in 2013?Chris Hill interviews Dave Williamson.
Jan 4, 2013 by Dave Williamson and Max MacalusoThis Blockbuster Drug Is Losing SteamOur analysts discuss one blockbuster drug facing serious headwinds.
Jan 4, 2013 by Dave Williamson, Brenton Flynn, and Max Macaluso1 Pharma Hoping Its Pipeline Bears FruitCan this big pharma get its drugs to market soon?
Jan 4, 2013 by Dave WilliamsonHow to Play the Booming Obesity Market in 2013Learn how to play the booming obesity market in 2013.
Jan 3, 2013 by Dave Williamson, Brenton Flynn, and Max MacalusoRisks Dendreon Investors Need to KnowWhat are the biggest problems facing this biotech today?
Jan 3, 2013 by Dave WilliamsonWhat You Need to Know About Big Pharma Find out what you need to know about big pharma.
Jan 2, 2013 by Dave WilliamsonThe Must-Watch Health Care Trends of 2013Learn about the must-watch health care trends of 2013.
Jan 2, 2013 by Dave WilliamsonThe Biggest Health Care Stories of 2012Watch The Biggest Healthcare Stories of 2012
Dec 26, 2012 by Dave WilliamsonWhy Aegerion Keeps WinningThe stock is hitting new 52-week highs post FDA approval.
Dec 21, 2012 by Dave Williamson, Brenton Flynn, and Max MacalusoWhy Berkshire Soured on Johnson & JohnsonSome of the factors that may have turned Buffett off to JNJ recently.
Dec 18, 2012 by Dave Williamson, Brenton Flynn, and Max MacalusoAnalyst Roundtable: Big Pharma Spinoffs Just how exposed is JNJ to the inherent risks of its industry?
Dec 18, 2012 by Dave Williamson and Max MacalusoAre the Shorts Right About Obesity Drugs?The two obesity-drug makers have caught the attention of short sellers. Are they right?
Dec 18, 2012 by Dave Williamson and Max MacalusoHemispherx's Unsurprising 45% PlungeHemispherx shares are down 45% after the release of a damning FDA briefing document.
Dec 17, 2012 by Dave Williamson and Max MacalusoThis Biotech Is Officially for SaleEnzon is looking into "strategic alternatives" to "maximize shareholder value." We know what that means.
Dec 17, 2012 by Dave Williamson and Max Macaluso1 Biotech Off to the RacesThis company just got a fast-track designation.
